MI-773 (SAR405838) is primarily investigated for its potential in cancer therapy. It functions as an MDM2 inhibitor, targeting the interaction between MDM2 and the tumor suppressor protein p53. By disrupting this interaction, MI-773 activates p53, leading to the induction of apoptosis in cancer cells. This mechanism is particularly relevant in cancers with wild-type p53, where MDM2 overexpression often leads to p53 inactivation. Preclinical studies have shown promising results in various cancer models, including solid tumors and hematologic malignancies. Its application is being explored in combination therapies to enhance efficacy and overcome resistance to conventional treatments. Ongoing research aims to optimize its therapeutic potential and evaluate its safety profile in clinical trials.

MI-773 (SAR405838) also serves as an important tool in laboratory studies of the MDM2-p53 pathway, aiding scientists in understanding cancer mechanisms and developing more effective therapies.